Biomarker-directed Neoadjuvant Therapy for Cisplatin-ineligible or Cisplatin-refusing Muscle-invasive Bladder Cancer: Phase I Bladder Cancer Signal Seeking Trial
Latest Information Update: 16 Aug 2022
Price :
$35 *
At a glance
- Drugs Infigratinib (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Biomarker; Therapeutic Use
- Acronyms (BLASST)-3
- 08 Aug 2022 Planned End Date changed from 25 Jan 2023 to 1 Dec 2023.
- 08 Aug 2022 Planned primary completion date changed from 25 Jul 2022 to 1 Dec 2022.
- 08 Aug 2022 Status changed from recruiting to withdrawn prior to enrolment.